116,591 Shares in Bausch Health Companies Inc. (NYSE:BHC) Acquired by Centiva Capital LP

Centiva Capital LP bought a new stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 116,591 shares of the company's stock, valued at approximately $951,000.

A number of other hedge funds also recently added to or reduced their stakes in BHC. Headlands Technologies LLC purchased a new stake in shares of Bausch Health Companies in the 2nd quarter worth about $35,000. MQS Management LLC purchased a new stake in shares of Bausch Health Companies in the second quarter valued at about $71,000. Certuity LLC acquired a new stake in shares of Bausch Health Companies in the second quarter valued at approximately $75,000. Bfsg LLC grew its position in shares of Bausch Health Companies by 46.7% in the second quarter. Bfsg LLC now owns 11,450 shares of the company's stock valued at $80,000 after purchasing an additional 3,643 shares during the last quarter. Finally, Kendall Capital Management acquired a new position in shares of Bausch Health Companies during the 2nd quarter worth approximately $87,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on BHC. Evercore ISI upgraded Bausch Health Companies to a "hold" rating in a research report on Tuesday, October 15th. Royal Bank of Canada raised their price objective on Bausch Health Companies from $10.00 to $11.00 and gave the stock a "sector perform" rating in a report on Friday, November 1st. Finally, StockNews.com upgraded Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $7.75.

Bausch Health Companies Stock Performance

Shares of BHC traded up $0.03 during trading hours on Friday, hitting $8.15. The stock had a trading volume of 835,041 shares, compared to its average volume of 2,801,307. Bausch Health Companies Inc. has a 12-month low of $3.96 and a 12-month high of $11.46. The firm has a market cap of $2.93 billion, a P/E ratio of -16.92 and a beta of 0.69. The company's fifty day simple moving average is $8.41 and its 200 day simple moving average is $7.17.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.10. The business had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The company's revenue was up 12.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.03 EPS. As a group, sell-side analysts predict that Bausch Health Companies Inc. will post 3.74 earnings per share for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.